Research advances in the mechanisms of fulvestrant resistance
10.3969/j.issn.1000-8179.2020.11.467
- Author:
Danni XU
1
Author Information
1. Department of Breast Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Drug resistance;
Endocrine therapy;
Fulvestrant;
Selective estrogen receptor degrader (SERD)
- From:
Chinese Journal of Clinical Oncology
2020;47(11):586-589
- CountryChina
- Language:Chinese
-
Abstract:
Fulvestrant is a selective estrogen receptor degrader (SERD), that can specifically bind to estrogen receptor (ER), block ER transcription activity, and induce the degradation of ER protein. However, along with its widespread use in breast cancer endocrine therapy, drug resistance does gradually develop. A better understanding of mechanisms on fulvestrant resistance and the exploration on precise targeted therapy is the key to breaking through treatment bottlenecks and subsequently improving the prognosis of patients. Here, we review research advances in the potential mechanisms of fulvestrant resistance and outline promising approaches such as combination therapy to overcome the resistance.
